Profile for Portugal Patent: 2352470

US Patent Family Members and Approved Drugs for Portugal Patent: 2352470

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
	Sep 14, 2029	Bayer Hlthcare	KYLEENA	levonorgestrel
	Sep 14, 2029	Bayer Hlthcare	MIRENA	levonorgestrel
	Sep 14, 2029	Bayer Hlthcare	SKYLA	levonorgestrel

Key insights for pharmaceutical patentability - Portugal patent PT2352470

Last updated: March 13, 2026

Drug Patent PT2352470: Scope, Claims, and Landscape Analysis

Patent Overview

Patent number PT2352470, filed in Portugal, appears to cover a pharmaceutical invention, likely targeting a specific active ingredient, formulation, or method of use. As a national patent, PT2352470 offers exclusivity within Portugal, but its relevance to international markets depends on whether it’s part of a broader patent family or has corresponding filings under the Patent Cooperation Treaty (PCT) or regional patent offices.

Scope of Patent PT2352470

The scope defines the boundaries of the invention’s protection, focusing primarily on claims. The patent likely encompasses:

• Composition claims: The specific formulation or combination of active ingredients.
• Method claims: Processes for preparing or administering the drug.
• Use claims: Indications or specific therapeutic methods.
• Device claims: If applicable, formulations involving delivery devices.

Based on typical patent structures, the scope is limited to the language articulated within the claims, which are the legal boundary lines of protection.

Key Claims Analysis

Without direct access to the full patent text, standard practice indicates the claims are structured as follows:

• Independent claims: Broadest, outlining the core invention—e.g., a pharmaceutical composition comprising a specific compound or combination.
• Dependent claims: Narrower, elaborating on specific embodiments—e.g., specific dosages, formulations, or methods of manufacture.

Sample Claims Breakdown (hypothetical):

Type	Content	Detail
Independent Claims	Composition of a novel drug with specified active compounds	Covering the chemical structure, dosage form, or delivery method
Dependent Claims	Variations, such as a specific excipient or storage condition	Narrower scope to specific embodiments

Patent Geography and Landscape

Portugal’s patent system links to the European Patent Office (EPO) via national routes, making it relevant for European-wide patent strategies.

• Regional patent landscape: The invention likely appears in other jurisdictions if the applicant seeks broader protection. Search strategies include WIPO PATENTSCOPE, Espacenet, and national patent databases.
• Patent family members: Checking for corresponding PCT applications or filings in key markets like the European Union, US, and China indicates the invention’s global reach.

Patent Landscape and Competitive Context

• Existing patents in the same class: Drugs targeting similar indications or containing similar compounds often cluster in specific classes (e.g., ATC classification).
• Major players: Companies filing similar patents include multinational pharma firms and biotech startups specializing in the therapeutic area.
• Legal status: PT2352470’s validity depends on maintenance fees and potential litigations; a status check on the Portuguese Patent Office or EPO databases reveals current standing.

Prior Art and Patentability

• The patent’s novelty relies on prior art searches around the chemical structures, formulations, and therapeutic methods.
• Non-obviousness depends on whether the claimed invention provides an unexpected benefit over existing alternatives.

Patent Lifecycle and Enforcement

• Validity duration for PT2352470 is 20 years from the filing date, subject to annual fees.
• Enforcement potential depends on infringement within Portugal and possible parallel protections through other jurisdictions.

Summary of Implications

• Protects a specific pharmaceutical invention within Portugal.
• May form part of a broader patent family, providing international exclusivity.
• The claims' breadth influences the scope of potential generic challenges.

Key Takeaways

• PT2352470’s scope hinges on its claims, which likely cover a specific formulation or method.
• Its landscape depends on filings in broader jurisdictions and the existence of prior art.
• The patent’s strength depends on claim drafting quality and legal status.

FAQs

1. What is the typical duration of a drug patent in Portugal?
   20 years from the filing date, subject to annual fees.

2. Can PT2352470 be challenged or invalidated?
   Yes. Challenges can stem from prior art submissions or legal arguments regarding patentability criteria.

3. How does this patent relate to international patent protection?
   As a national patent, it provides protection only in Portugal unless linked to broader filings through PCT or regional patents.

4. What factors influence the strength of the patent claims?
   Clarity, novelty, non-obviousness, and the scope of language used in the claims.

5. Is there a way to determine if PT2352470 remains enforceable?
   Yes, by checking the Portuguese Patent Office’s records for maintenance fee payments and legal status updates.

---

References

1. European Patent Office. (2022). Espacenet patent database. Retrieved from https://worldwide.espacenet.com/
2. Portuguese Institute of Industrial Property (INPI). (2022). Patent law and procedures. Retrieved from https://inpi.justica.gov.pt/
3. World Intellectual Property Organization. (2022). PCT Patent Application Search. Retrieved from https://patentscope.wipo.int/search/en/search.jsf
4. WIPO. (2022). Patent Landscape Report: Pharmaceutical Patents. Retrieved from https://www.wipo.int/standards/en/landscape.html